Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
12 December, 2018 15:28 IST
Glenmark Pharm quarterly earnings fall 17.5%
Source: IRIS | 30 May, 2018, 10.54AM
Comments  |  Post Comment

Earnings per share for the quarter stood at Rs 5.37, registering 17.51% decline over previous year period.

''While FY 2018 was a challenging year mainly on account of pricing pressure in the U.S., our other key markets like Europe and India performed well on the back of new product launches. Even though we expect pricing pressure to persist, we are glad that FY 2019 has started on a positive note for us with approvals for some interesting products in the U.S.,'' said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals. (Q,N,C,F)* He further added, ''We recently filed our first New Drug Application (NDA) for Ryaltris in the U.S, which is a milestone in Glenmark's journey and marks our first step towards the transition to a specialty and innovative drugs company. We believe our strong R&D pipeline of novel assets will help propel growth in the long run.''

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Ashok Leyland signs defence agreement with ELBIT Systems - 12-Dec-2018 09:41
Wipro launches automotive innovation center in Michigan - 12-Dec-2018 09:37
Liva Pharmaceuticals gets USFDA approval for its sANDA - Ranitidine Injection - 12-Dec-2018 09:35
Dr Reddy's Labs launches Omeprazole tablets in US market - 12-Dec-2018 09:31
Strides Vivimed JV receives consent for Albendazole tablets - 12-Dec-2018 09:27
Unichem Lab gets tentative nod for Tadalafil tablets - 12-Dec-2018 09:25
Zydus Wellness gets CCI approval for acquisition of Heinz India - 12-Dec-2018 09:20
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:26
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:24
Lupin receives tentative USFDA approval for Apixaban tablets - 11-Dec-2018 09:20
Lupin receives EIR from USFDA for Indore facility - 10-Dec-2018 16:10
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer